NCT06307080 Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
| NCT ID | NCT06307080 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2023-10-08 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2023-10-08 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.
Eligibility Criteria
Inclusion Criteria: 1. age 18-70 years old, gender is not limited; 2. Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver; 3. Imaging evaluable tumors with safe access to puncture; 4. The number of half liver tumors ≤3 and the size of each tumor ≤3 cm; 5. ECOG PS score ≤2 points, expected survival \> 3 months. Exclusion Criteria: 1. Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice; 2. The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume; 3. Expected survival \< 3 months; 4. serious heart, lung, liver and kidney dysfunction and coagulation dysfunction; 5. Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study; 6. refractory ascites, pleural fluid or bad fluid; 7. Pregnancy or breastfeeding; 8. The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.
Contact & Investigator
Long Jiang, MD
PRINCIPAL INVESTIGATOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Frequently Asked Questions
Who can join the NCT06307080 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06307080 currently recruiting?
Yes, NCT06307080 is actively recruiting participants. Contact the research team at jiang.long@shgh.cn for enrollment information.
Where is the NCT06307080 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06307080 clinical trial?
NCT06307080 is sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The principal investigator is Long Jiang, MD at Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.